American Renal Associates Holdings, Inc (NYSE:ARA) – Research analysts at SunTrust Banks cut their FY2017 EPS estimates for American Renal Associates Holdings in a note issued to investors on Wednesday. SunTrust Banks analyst D. Macdonald now anticipates that the company will earn $0.57 per share for the year, down from their prior forecast of $0.58. SunTrust Banks has a “Buy” rating and a $18.00 price target on the stock. SunTrust Banks also issued estimates for American Renal Associates Holdings’ Q4 2017 earnings at $0.16 EPS, Q2 2018 earnings at $0.19 EPS, Q3 2018 earnings at $0.20 EPS, Q4 2018 earnings at $0.23 EPS, FY2018 earnings at $0.73 EPS, Q1 2019 earnings at $0.16 EPS, Q2 2019 earnings at $0.22 EPS, Q3 2019 earnings at $0.24 EPS and FY2019 earnings at $0.86 EPS.

American Renal Associates Holdings (NYSE:ARA) last posted its quarterly earnings data on Tuesday, November 14th. The company reported $0.19 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.16 by $0.03. The company had revenue of $187.71 million during the quarter, compared to analysts’ expectations of $194.60 million. American Renal Associates Holdings had a negative net margin of 2.15% and a positive return on equity of 15.84%. The firm’s revenue for the quarter was down 2.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.28 earnings per share.

ILLEGAL ACTIVITY WARNING: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/11/17/american-renal-associates-holdings-inc-forecasted-to-earn-fy2017-earnings-of-0-57-per-share-ara.html.

Separately, Zacks Investment Research upgraded shares of American Renal Associates Holdings from a “hold” rating to a “buy” rating and set a $13.00 target price for the company in a research report on Thursday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $18.00.

Shares of American Renal Associates Holdings (NYSE ARA) traded up $0.41 during midday trading on Friday, hitting $13.03. 334,046 shares of the stock were exchanged, compared to its average volume of 147,346. The firm has a market capitalization of $313.66, a PE ratio of 14.88, a price-to-earnings-growth ratio of 0.88 and a beta of 3.64. The company has a debt-to-equity ratio of 3.69, a current ratio of 1.17 and a quick ratio of 1.14. American Renal Associates Holdings has a 1-year low of $9.91 and a 1-year high of $24.94.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Atria Investments LLC raised its position in shares of American Renal Associates Holdings by 2.2% in the second quarter. Atria Investments LLC now owns 10,943 shares of the company’s stock valued at $203,000 after buying an additional 233 shares during the last quarter. Schwab Charles Investment Management Inc. raised its position in shares of American Renal Associates Holdings by 0.7% in the second quarter. Schwab Charles Investment Management Inc. now owns 39,132 shares of the company’s stock valued at $726,000 after buying an additional 285 shares during the last quarter. Rhumbline Advisers raised its position in shares of American Renal Associates Holdings by 2.7% in the second quarter. Rhumbline Advisers now owns 13,383 shares of the company’s stock valued at $248,000 after buying an additional 354 shares during the last quarter. Alliancebernstein L.P. raised its position in shares of American Renal Associates Holdings by 3.0% in the second quarter. Alliancebernstein L.P. now owns 13,900 shares of the company’s stock valued at $258,000 after buying an additional 400 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its position in American Renal Associates Holdings by 19.7% during the second quarter. The Manufacturers Life Insurance Company now owns 8,778 shares of the company’s stock worth $162,000 after purchasing an additional 1,443 shares during the last quarter. Institutional investors and hedge funds own 89.98% of the company’s stock.

About American Renal Associates Holdings

American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.

Earnings History and Estimates for American Renal Associates Holdings (NYSE:ARA)

Receive News & Stock Ratings for American Renal Associates Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates Holdings Inc and related stocks with our FREE daily email newsletter.